News | October 30, 2022
Granules India plans H2 FY 2022-23 R&D spend in Rs. 80-90 Cr
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
The two overhead tanks commissioned at a cost of Rs 57 lakh will be maintained by the village panchayats.
Granules now have a total of 51 ANDA approvals from US FDA (49 Final approvals and 2 tentative approvals).
Pharmaceutical manufacturer uses Veeam solutions to accelerate mission-critical backups by 95% and restore data in minutes, not hours
Granules India has reported consolidated financial results for the period ended December 31, 2021
He has over 29 years of experience in the field of manufacturing, R&D, business and customer service management
Sucharita brings with her a rich and varied experience of two decades in Information Technology and Financial Services
One batch has 11.4 million units of Naproxen tablets out of which 0.9 million units that were released into the market were recalled
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
Subscribe To Our Newsletter & Stay Updated
